Literature DB >> 26239494

Relative Timing Between Kappa Opioid Receptor Activation and Cocaine Determines the Impact on Reward and Dopamine Release.

Elena H Chartoff1, Shayla R Ebner2, Angela Sparrow1, David Potter1, Phillip M Baker3, Michael E Ragozzino2, Mitchell F Roitman2.   

Abstract

Negative affective states can increase the rewarding value of drugs of abuse and promote drug taking. Chronic cocaine exposure increases levels of the neuropeptide dynorphin, an endogenous ligand at kappa opioid receptors (KOR) that suppresses dopamine release in the nucleus accumbens (NAc) and elicits negative affective states upon drug withdrawal. However, there is evidence that the effects of KOR activation on affective state are biphasic: immediate aversive effects are followed by delayed increases in reward. The impact of KOR-induced affective states on reward-related effects of cocaine over time is not known. We hypothesize that the initial aversive effects of KOR activation increase, whereas the delayed rewarding effects decrease, the net effects of cocaine on reward and dopamine release. We treated rats with cocaine at various times (15 min to 48 h) after administration of the selective KOR agonist salvinorin A (salvA). Using intracranial self-stimulation and fast scan cyclic voltammetry, we found that cocaine-induced increases in brain stimulation reward and evoked dopamine release in the NAc core were potentiated when cocaine was administered within 1 h of salvA, but attenuated when administered 24 h after salvA. Quantitative real-time PCR was used to show that KOR and prodynorphin mRNA levels were decreased in the NAc, whereas tyrosine hydroxylase and dopamine transporter mRNA levels and tissue dopamine content were increased in the ventral tegmental area 24 h post-salvA. These findings raise the possibility that KOR activation-as occurs upon withdrawal from chronic cocaine-modulates vulnerability to cocaine in a time-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26239494      PMCID: PMC4748424          DOI: 10.1038/npp.2015.226

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  69 in total

1.  Resolving neurotransmitters detected by fast-scan cyclic voltammetry.

Authors:  Michael L A V Heien; Michael A Johnson; R Mark Wightman
Journal:  Anal Chem       Date:  2004-10-01       Impact factor: 6.986

2.  Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect.

Authors:  Samuel S Newton; Johannes Thome; Tanya L Wallace; Yukihikko Shirayama; Lee Schlesinger; Norio Sakai; Jingshan Chen; Rachael Neve; Eric J Nestler; Ronald S Duman
Journal:  J Neurosci       Date:  2002-12-15       Impact factor: 6.167

3.  An opponent-process theory of motivation. I. Temporal dynamics of affect.

Authors:  R L Solomon; J D Corbit
Journal:  Psychol Rev       Date:  1974-03       Impact factor: 8.934

Review 4.  Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.

Authors:  Bronwyn M Kivell; Amy W M Ewald; Thomas E Prisinzano
Journal:  Adv Pharmacol       Date:  2014

5.  Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.

Authors:  Stephen D Mague; Andrea M Pliakas; Mark S Todtenkopf; Hilarie C Tomasiewicz; Yan Zhang; William C Stevens; Robert M Jones; Philip S Portoghese; William A Carlezon
Journal:  J Pharmacol Exp Ther       Date:  2003-04       Impact factor: 4.030

6.  Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist U-50488 in rats.

Authors:  Shayla E Russell; Anna B Rachlin; Karen L Smith; John Muschamp; Loren Berry; Zhiyang Zhao; Elena H Chartoff
Journal:  Biol Psychiatry       Date:  2013-10-03       Impact factor: 13.382

7.  Effects of the kappa opioid agonist U50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys.

Authors:  S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2004-04-27       Impact factor: 4.530

8.  Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Bridget F Grant; Frederick S Stinson; Deborah A Dawson; S Patricia Chou; Mary C Dufour; Wilson Compton; Roger P Pickering; Kenneth Kaplan
Journal:  Arch Gen Psychiatry       Date:  2004-08

Review 9.  Agonist-induced regulation and trafficking of kappa opioid receptors.

Authors:  Lee-Yuan Liu-Chen
Journal:  Life Sci       Date:  2004-06-18       Impact factor: 5.037

10.  Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats.

Authors:  Marco Pravetoni; Paul R Pentel; David N Potter; Elena H Chartoff; Laura Tally; Mark G LeSage
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

View more
  23 in total

Review 1.  Role of the Dynorphin/Kappa Opioid Receptor System in the Motivational Effects of Ethanol.

Authors:  Rachel I Anderson; Howard C Becker
Journal:  Alcohol Clin Exp Res       Date:  2017-06-05       Impact factor: 3.455

2.  Contribution of Dynorphin and Orexin Neuropeptide Systems to the Motivational Effects of Alcohol.

Authors:  Rachel I Anderson; David E Moorman; Howard C Becker
Journal:  Handb Exp Pharmacol       Date:  2018

3.  Early-Life Social Isolation Stress Increases Kappa Opioid Receptor Responsiveness and Downregulates the Dopamine System.

Authors:  Anushree N Karkhanis; Jamie H Rose; Jeffrey L Weiner; Sara R Jones
Journal:  Neuropsychopharmacology       Date:  2016-02-10       Impact factor: 7.853

4.  Females are less sensitive than males to the motivational- and dopamine-suppressing effects of kappa opioid receptor activation.

Authors:  Sineadh M Conway; Daniel Puttick; Shayla Russell; David Potter; Mitchell F Roitman; Elena H Chartoff
Journal:  Neuropharmacology       Date:  2018-12-05       Impact factor: 5.250

5.  "Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats".

Authors:  Marta Valenza; Eduardo R Butelman; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2017-05-27       Impact factor: 4.530

6.  Switch from excitatory to inhibitory actions of ethanol on dopamine levels after chronic exposure: Role of kappa opioid receptors.

Authors:  Anushree N Karkhanis; Kimberly N Huggins; Jamie H Rose; Sara R Jones
Journal:  Neuropharmacology       Date:  2016-07-20       Impact factor: 5.250

7.  Social defeat disrupts reward learning and potentiates striatal nociceptin/orphanin FQ mRNA in rats.

Authors:  Andre Der-Avakian; Manoranjan S D'Souza; David N Potter; Elena H Chartoff; William A Carlezon; Diego A Pizzagalli; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2017-03-09       Impact factor: 4.530

Review 8.  The effects of early life stress on motivated behaviors: A role for gonadal hormones.

Authors:  Samantha R Eck; Debra A Bangasser
Journal:  Neurosci Biobehav Rev       Date:  2020-10-03       Impact factor: 8.989

Review 9.  Dynorphin and its role in alcohol use disorder.

Authors:  Anushree N Karkhanis; Ream Al-Hasani
Journal:  Brain Res       Date:  2020-02-28       Impact factor: 3.252

10.  Dopamine and opioid systems interact within the nucleus accumbens to maintain monogamous pair bonds.

Authors:  Shanna L Resendez; Piper C Keyes; Jeremy J Day; Caely Hambro; Curtis J Austin; Francis K Maina; Lori N Eidson; Kirsten A Porter-Stransky; Natalie Nevárez; J William McLean; Morgan A Kuhnmuench; Anne Z Murphy; Tiffany A Mathews; Brandon J Aragona
Journal:  Elife       Date:  2016-07-02       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.